Clinical trial · Interventional
Nerve Function in Older Diabetic Patients Who Are Undergoing Chemotherapy for Metastatic Solid Tumors
Impact of Treatment With Taxane or Platinum-Containing Regimens on Peripheral Nerve Functioning in Older Cancer Patients With Diabetes: An Exploratory Study
NCT00263861CI-TRIAL-00003535completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Learning about the side effects of chemotherapy may help plan treatment and may help patients live more comfortably. PURPOSE: This clinical trial is studying nerve function in older diabetic patients who are undergoing chemotherapy for metastatic solid tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neurotoxicity | — | UNRESOLVED | — |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| management of therapy complications | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (6)
- measure
- Cutaneous sensation as measured by Semmes-Weinstein monofilaments
- timeFrame
- baseline, every 3 weeks for 4 courses, and then 2 months after completion of study treatment
- measure
- Gait and balance as measured by Tinetti Performance Oriented Assessment of Gait and Balance Instrument
- timeFrame
- baseline, every 3 weeks for 4 courses, and then 2 months after completion of study treatment
- measure
- Vibration as measured by tuning fork
- timeFrame
- baseline, every 3 weeks for 4 courses, and then 2 months after completion of study treatment
- measure
- Lower extremity muscle strength as measured by Dynamometer
- timeFrame
- baseline, every 3 weeks for 4 courses, and then 2 months after completion of study treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of solid tumor * Metastatic disease (stage IV) * Planning neoadjuvant or adjuvant treatment of locoregional definitive or systemic therapy comprising ≥ 1 of the following: * Taxane (paclitaxel or docetaxel) * Platinum (cisplatin, carboplatin, or oxaliplatin) * Diagnosis of type I or II diabetes mellitus PATIENT CHARACTERISTICS: Performance status * Not specified Life expectancy * Not specified Hematopoietic * Not specified Hepatic * Not specified Renal * Not specified Other * No other disease that reduces peripheral nerve function (e.g., HIV/AIDS, uremia, spinal injuries, alcoholism, or CNS problems) PRIOR CONCURRENT THERAPY: Chemotherapy * See Disease Characteristics * No prior chemotherapy * No prior or concurrent neurotoxic drugs (i.e., vincristine)
References
Publications (0)
Data not yet available
No reference posted for this study.